

1 **Same-day versus rapid ART initiation in HIV-positive individuals**
2 **presenting with symptoms of tuberculosis: protocol for an open-label**
3 **randomized non-inferiority trial in Lesotho and Malawi**

4

5 Felix Gerber^{1,2*}, Robina Semphere^{3,4}, Blaise Lukau⁵, Palesa Mahlatsi⁵, Timeo Mtenga^{3,4}, Tristan Lee^{2,6},
6 Maurus Kohler^{1,2}, Tracy R. Glass^{2,6}, Alain Amstutz^{1,2}, Mamello Molatelle⁷, Peter MacPherson^{8,9,11},
7 Nthuseng Bridgett Marake¹⁰, Marriot Nliwasa^{3,4}, Irene Ayakaka⁵, Rachael Burke^{9,11¶}, Niklaus Labhardt^{1,2¶}

8 ¹ Division of Clinical Epidemiology University Hospital Basel

9 ² University of Basel

10 ³ Helse Nord Tuberculosis Initiative

11 ⁴ Kamuzu University of Health Sciences

12 ⁵ SolidarMed Lesotho

13 ⁶ Swiss Tropical and Public Health Institute

14 ⁷ Seboche Mission Hospital Laboratory

15 ⁸ School of Health and Wellbeing, University of Glasgow

16 ⁹ Malawi-Liverpool-Wellcome Programme

17 ¹⁰ Ministry of Health Lesotho

18 ¹¹ London School of Hygiene and Tropical Medicine

19

20

21 * Corresponding author

22 e-mail: felix.gerber@usb.ch

23

24 • Sponsor-investigator

25 e-mail: niklaus.labhardt@usb.ch

26

27 ¶ These authors contributed equally to this work

28

29 Version 1.0: June 30, 2023

30

31 **Abstract**

32 **Background**

33 In absence of contraindications, same-day initiation (SDI) of antiretroviral therapy (ART) is
34 recommended for people testing HIV-positive who are ready to start treatment. Until 2021, World
35 Health Organization (WHO) guidelines considered the presence of TB symptoms (presumptive TB) a
36 contraindication to SDI due to the risk of TB-immune reconstitution inflammatory syndrome (TB-IRIS).
37 To reduce TB-IRIS risk, ART initiation was recommended to be postponed until results of TB
38 investigations were available, and TB treatment initiated if active TB was confirmed. In 2021, the WHO
39 guidelines changed to recommending SDI even in the presence of TB symptoms without awaiting results
40 of TB investigations based on the assumption that TB investigations often unnecessarily delay ART
41 initiation, increasing the risk for pre-ART attrition from care, and noting that the clinical relevance of TB-
42 IRIS outside the central nervous system remains unclear. However, this guideline change was not based
43 on conclusive evidence, and it remains unclear whether SDI of ART or TB test results should be prioritized
44 in people with HIV (PWH) and presumptive TB.

45 **Design and methods**

46 SaDAPT is an open-label, pragmatic, parallel, 1:1 individually randomized, non-inferiority trial comparing
47 two strategies for the timing of ART initiation in PWH with presumptive TB (“ART first” versus “TB results
48 first”). PWH in Lesotho and Malawi, aged 12 years and older (re)initiating ART who have at least one TB
49 symptom (cough, fever, night sweats or weight loss) and no signs of intracranial infection are eligible.
50 After a baseline assessment, participants in the “ART first” arm will be offered SDI of ART, while those
51 in the “TB results first” arm will be offered ART only after active TB has been confirmed or refuted. We
52 hypothesize that the “ART first” approach is safe and non-inferior to the “TB results first” approach with
53 regard to HIV viral suppression (<400 copies/ml) six months after enrolment. Secondary outcomes
54 include retention in care and adverse events consistent with TB-IRIS.

55 **Expected outcomes**

56 SaDAPT will provide evidence on the safety and effects of SDI of ART in PWH with presumptive TB in a
57 pragmatic clinical trial setting.

58 **Trial registration**

59 The trial has been registered on clinicaltrials.gov (NCT05452616; July 11 2022).

60 **Introduction**

61 Global efforts have led to a substantial decline in HIV transmission and mortality over the past decades.

62 A main driver of this success has been the scaling up of antiretroviral therapy (ART) care in resource-

63 constrained settings using a public health approach, which includes the use of standardized treatment

64 regimens with faster and simplified initiation procedures (1). Nevertheless, HIV remains a major cause

65 of morbidity and mortality, causing 650'000 deaths in 2021 (2). The leading cause of mortality in people

66 with HIV (PWH) is tuberculosis (TB) causing an estimated 187'000 deaths in PWH in 2021 (2,3).

67 Since 2017, the World Health Organization (WHO) has recommended rapid ART initiation – defined as

68 initiating ART within seven days of a positive HIV test result – to improve access to ART and to reduce

69 pre-treatment loss to follow-up (4). Where possible, this should include starting ART on the same day

70 the positive HIV result is obtained. For people without clinical contraindications, rapid and same-day

71 initiation (SDI) of ART are safe, reduce pre-treatment loss to follow up, improve retention in care, and

72 are generally preferred by patients compared to a longer delay between HIV diagnosis and ART (5–9).

73 However, earlier initiation of ART, especially before the exclusion of possible opportunistic infections,

74 may increase the risk of immune reconstitution inflammatory syndrome (IRIS) (10–12). IRIS is an acute

75 inflammatory condition, often presenting with worsening or new onset of symptoms of underlying

76 opportunistic infections, caused by an exaggerated inflammatory response after restoration of immunity

77 through ART. The risk for development of IRIS increases with lower levels of CD4 cells at baseline, the

78 presence of opportunistic infections – especially TB – and with earlier initiation of ART if opportunistic

79 infections are present (10,12–15). IRIS is most dangerous in the presence of central nervous system

80 (CNS) infections, where SDI is specifically contraindicated (16–18).

81 For PWH, routine TB symptom screening is recommended using the WHO four-symptom screen (W4SS),

82 which includes cough, fever, night sweats and weight loss (19–22). People with at least one of the four

83 symptoms are defined as having presumptive TB and should have TB tests to refute or confirm active TB
84 disease. The prevalence of TB symptoms among PWH not taking ART was estimated at 71% in a
85 systematic review, although with considerable variation between studies (20). Studies in Kenya and
86 South Africa have shown that sputum tests confirmed active TB in only 5%-19% of people who had TB
87 symptoms when presenting at HIV services before starting ART (23–25).

88 Prior to 2021, WHO guidelines considered the presence of TB symptoms as a contraindication to SDI and
89 recommended deferral of ART initiation until active TB was ruled out or TB treatment was initiated (26).

90 In practice, because TB symptoms are so common and confirming or refuting TB within one day is often
91 not possible in routine care, this recommendation was a considerable barrier to SDI for a significant
92 proportion of PWH. Whilst delaying ART until TB tests results are available might be clinically reasonable
93 in optimal settings, it may cause harm in routine practice as delays between HIV diagnosis and ART
94 initiation are associated with attrition from care, pre-treatment mortality and substantial out-of-pocket
95 costs for patients, especially in remote areas where walking distances or transport costs to clinics are
96 high (27–29). In these settings, offering SDI to PWH with presumptive TB while TB tests are concurrently
97 done may be a valuable strategy to engage and retain more patients in care and thus improve overall
98 clinical outcomes. Based on this reasoning, WHO included the clinical consideration to start ART in PWH
99 with presumptive TB, but no signs of CNS infection, while rapidly investigating for TB in their guidelines
100 since 2021 (19,30). This recommendation was issued despite a systematic review informing these
101 guidelines concluding that “there is insufficient evidence about whether presence of TB symptoms
102 should lead to ART start being deferred or not” because the effects on key health outcomes, such as
103 mortality, TB and HIV outcomes had not been investigated (31).

104 The objective of the SaDAPT trial is to address this evidence gap by assessing the effect of SDI of ART
105 (“ART first”) versus rapid ART initiation after TB results are available (“TB results first”) on HIV viral
106 suppression six months after enrolment, and on other relevant health outcomes including mortality,

107 serious adverse events (SAEs), and adverse events consistent with TB-IRIS (adverse events of special
108 interest [AESI]), among PWH with presumptive TB and no signs of CNS infection.

109 **Methods**

110 **Design and setting**

111 SaDAPT is an open-label, pragmatic, parallel, 1:1 individually randomized, non-inferiority trial conducted
112 at primary care clinics in urban Blantyre, Malawi, and in primary and secondary level facilities in five
113 districts in Lesotho (urban and rural). HIV prevalence is estimated to be 21% in Lesotho and 12% in
114 Blantyre, Malawi (2,32). TB incidence is 650 per 100'000 person-years in Lesotho and TB prevalence has
115 recently been estimated at 150 per 100'000 adults in Blantyre (2,33). Both Malawi and Lesotho have a
116 public health approach (1,34) to ART delivery with HIV care being task-shifted to nurses and to lower
117 cadres of healthcare staff.

118 **Eligibility criteria and enrolment**

119 The SaDAPT trial enrolls consenting PWH, 12 years or older, not taking ART (either ART naïve or
120 interruption for 90 days or more), who have at least one TB symptom according to the W4SS (20).
121 Routine staff at study facilities refer PWH newly diagnosed or after ART interruption of at least 90 days
122 to study staff for eligibility screening. After obtaining oral screening consent, eligibility screening is done
123 using a questionnaire in the electronic data collection tool (Research Electronic Data Capture [REDCap]
124 platform (35)). Individuals with a medical condition requiring admission to hospital or referral to a
125 higher-level health facility at enrolment, having symptoms or clinical signs of CNS infection, not planning
126 to receive follow-up care at the study facility, reporting to be pregnant, or to be taking TB treatment, TB
127 preventive therapy (TPT), or treatment for cryptococcal meningitis are excluded (Fig 1). In participants
128 with a CD4 cell count below 200 cells/mm³ or participants who are severely wasted or unable to walk
129 unaided without CD4 results available at the time of screening, a serum cryptococcal antigen (CrAg) test

130 is performed and those with a positive or missing CrAg result are excluded from the trial. After screening,
131 eligible participants are approached for written informed consent. For adolescents below 18 years, a
132 guardian consent is asked in addition to the adolescent's assent. Illiterate individuals give consent with
133 a thumbprint countersigned by a witness not involved in the study.

134 **Figure 1 SPIRIT schedule of enrolment, interventions, and assessments**

135 Timing of the TB results review is depending on local routine procedures. Tracing only applies to
136 participants without documented HIV viral load between week 22 and 30. HIV viral load will be measured
137 during tracing if participant was found and no viral load result between week 22 and 30 became
138 available. SAE: Serious Adverse Event, AESI: Adverse Event of Special Interest, CrAg: Cryptococcal
139 antigen test.

140 **Baseline assessment**

141 At baseline, we collect demographic, socioeconomic and clinical information on HIV and ART history,
142 document CD4 cell count and, if possible, take a first TB sputum sample for analysis by nucleic acid
143 amplification test (NAAT, Xpert[®] MTB/RIF or Xpert[®] MTB/RIF Ultra [Cepheid, USA]). Other investigations
144 (for example serum C-reactive protein (CRP), chest X-ray, urine lipoarabinomannan assay (LAM) or
145 additional sputum analysis), ART counselling, and prescribing and dispensing of ART, TB preventive
146 treatment (TPT) and cotrimoxazole preventive treatment (CPT) are done at the discretion of routine staff
147 providing ART care. At present, in Malawi, urine LAM is available but rarely used, while chest X-ray and
148 CRP are unavailable at the study sites. At the study sites in Lesotho, urine LAM is sometimes available
149 but rarely used, CRP is not available, and chest X-ray is available most of the time. NAATs are routinely
150 available at all study sites with varying turnaround times. We aim to have at least one sputum NAAT
151 result documented for every participant. However, if NAAT is not available, active TB may be confirmed
152 or refuted based upon clinical and/or radiological findings as per local routine practices to avoid delay
153 of diagnostic and therapeutic procedures through trial participation.

154 **Randomization and blinding**

155 After assessment of baseline characteristics and initiation of TB investigations, participants are
156 randomized using block randomization with varying block sizes, stratified by country, based on
157 randomization lists that were generated by an independent statistician and uploaded into the Research
158 Electronic Data Capture (REDCap) (35) study database. Site investigators allocate participants to the
159 interventions using the REDCap randomization module on password protected study tablets.

160 Because of the nature of the study and the interventions offered, it is not feasible to blind participants
161 or site investigators to group allocation. Viral load results, the primary endpoint, are measured by
162 laboratory staff who are not directly involved in the study and remain blinded to trial arm allocation.
163 The endpoint of adverse events consistent with TB-IRIS is assessed through review of clinical reports by
164 an independent expert panel blinded to arm allocation, as the assessment of this endpoint is more
165 subjective and therefore vulnerable to bias if allocation was known.

166 **Trial intervention**

167 The trial tests two different strategies for the timing of ART initiation relative to completion of initial TB
168 investigations (“TB results first” versus “ART first”).

169 **TB results first arm**

170 For participants in the “TB results first” arm, ART initiation is deferred until TB investigations are
171 complete and active TB has been refuted or confirmed, with the aim to start ART within seven days after
172 first presentation (i.e. rapid ART initiation, Fig 2). The duration until investigations for active TB are
173 complete, depends on individual clinical presentation, local routine procedures, and availability of TB
174 examinations. For most participants, TB investigations is considered complete after a NAAT sputum
175 result is obtained. However, in some cases, further examinations after a negative NAAT result is
176 required, while others might be diagnosed based on clinical and/or radiological findings without NAAT

177 result. For some participants, for example those presenting in the morning hours at a study site with
178 quick NAAT return times, the TB investigations are completed on the day of presentation and ART may
179 be initiated on the same day after results are available. For other participants, TB investigations are more
180 time consuming, and follow-up visit on another day may be required to discuss results with the
181 participant and initiate treatment. The study team does not influence duration or interpretation of TB
182 investigations, but documents the routine procedures and results.

183 **ART first arm**

184 For participants in the “ART first” arm, SDI of ART is offered regardless of whether TB investigations have
185 been completed or not (Fig 2). Routine clinical staff is responsible for communication of TB test results
186 and initiation of TB treatment in case of positive results.

187 **Fig 2. Consort chart of the SaDAPT trial.**

188 CNS: Central nervous system, CrAg: Cryptococcal antigen, CPT: Cotrimoxazole preventive therapy, TPT:
189 Tuberculosis preventive therapy, SAE: Serious adverse event, AESI: Adverse event of special interest, VL:
190 viral load

192 **Follow-up and endpoint assessment**

193 The primary outcome is HIV viral suppression (<400 copies/mL), measured at six months (measurement
194 window 22 to 40 weeks) after enrolment (table 1). VL results are obtained from laboratory reports at
195 the study facility or a referral facility (in case of transfer), or from dried blood spot (DBS) samples for
196 participants without documented clinic visit but found during home visit tracing.

197 Secondary endpoints are initiation of ART by 7 and 28 days after enrolment, retention and engagement
198 in ART care, disengagement from ART care and loss to follow-up six months after enrolment, non-
199 traumatic mortality, serious adverse events (SAEs), adverse events consistent with TB-IRIS (adverse
200 events of special interest [AESIs]), and incidence of active TB disease (see table 1 for exact definitions).

201 Participants are instructed to contact the study team if they become unwell or are admitted to hospital
202 over the course of the study. Routine staff in ART clinics is referring participants to trial staff for study
203 documentation in case of relevant health problems during the follow-up period (passive surveillance for
204 SAEs and AESIs). The trial team does not intervene in routine care, but documents relevant events and
205 therapeutic procedures in the trial database, for example the date and circumstances of ART, TPT or TB
206 treatment initiation. There are no trial-specific scheduled visits before the endpoint window and the site
207 investigators are not tracing participants prior to 30 weeks from enrolment.

208 Twenty-eight days after enrolment, a review of routine registers is conducted by the study team to
209 ensure that relevant data, including information on ART initiation, TB tests and TPT and TB treatment
210 initiation, are fully captured in the trial database.

211 The final study visit (22-30 weeks after enrolment) is scheduled together with the routine 6-month ART
212 refill and viral load measurement visit, where possible. In addition to routine adherence counseling, ART
213 refill and viral load measurement, site investigators take a targeted clinical history including inquiry

214 about ART and TB status, current health status, and possible SAEs since enrolment. For all participants,
215 a final clinic register review is conducted 30 weeks after enrolment to ensure that all relevant routinely
216 collected data since enrolment (SAEs, AESIs, ART status, viral load) are documented in the trial database
217 covering the full follow-up time of 30 weeks.

218 After week 30, participants without a documented viral load measurement at their study facility
219 between week 22 and 30 after enrolment are traced via phone calls and/or home visits if required to
220 ascertain their outcome. For participants with a reported transfer to another facility, viral load results
221 are requested from the transfer facility. Participants without reported transfer are visited at home or
222 asked to return to the study facility for the collection of viral load samples between week 31 and week
223 40. If a participant has died, the circumstances of death (in particular whether death was due to trauma
224 and whether TB was diagnosed prior to death) is recorded.

225

226 **Table 1. Overview of endpoints.**

Primary endpoint :
<ul style="list-style-type: none">- HIV viral suppression <400 copies/mL 26 (22 – 40) weeks after enrolment (obtained from laboratory reports at study facility or referral facility (in case of transfer), or from dried blood spot (DBS) sample for participants found during home visit tracing)
Secondary endpoints:
<ul style="list-style-type: none">- Retention in care 26 (22 – 30) weeks after enrolment, defined as having a documented clinic visit between 22 and 30 weeks after enrolment- Engagement in care 26 (22 – 30) weeks after enrolment, defined as reporting regular ART intake, between 22 and 30 weeks after enrolment- Disengagement from care 26 (22 – 30) weeks after enrolment, defined as not being engaged in care but reached through patient tracing- Lost to follow-up 26 (22 – 30) weeks after enrolment, defined as not being retained in care and not reached through tracing- Non-traumatic mortality, incidence of SAEs and of adverse events consistent with TB-IRIS (AESIs) during the first 30 weeks after enrolment- Incidence of TB disease (microbiologically confirmed and/or clinical diagnosis) during the first 30 weeks after enrolment, defined as any TB diagnosis after enrolment not classified as prevalent TB at enrolment- ART initiation by 7 and 28 days after enrolment
Exploratory endpoints:
<ul style="list-style-type: none">- Clinical characteristics of participants with non-traumatic hospitalizations and deaths in PWH with presumptive TB- Prevalence of active TB diagnosed at enrolment, defined as TB diagnosed clinically or microbiologically through the TB investigations initiated at enrolment and completed up to a maximum of 28 days after enrolment.- HIV viral suppression at 26 (22 – 40) weeks using different thresholds (<40 copies/mL; <100 copies/mL; <1000 copies/mL)

227 SAE: Serious Adverse Event; AESI: Adverse Event of Special Interest

228

229 **Statistical analysis and sample size**

230 The primary analysis is the comparison of the proportion of participants with HIV viral suppression (<400
231 copies/ml) between the two study arms. For this analysis, we will use a logistic regression model
232 adjusted for country (the randomization stratification factor) (36). Additionally, we will adjust for
233 baseline characteristics if found to be unbalanced between study arms (37). For the non-inferiority
234 comparison, a confidence interval approach will be used. If the lower bound of the 95% confidence
235 interval for the risk difference does not include the non-inferiority margin of 10%, then the intervention
236 will be considered non-inferior. The primary analysis will be done in a modified intention to treat
237 population (mITT), including everyone randomized except participants found to have been ineligible for

238 the trial only after randomization and in a per-protocol (PP) population including all participants who
239 completed trial procedures without a major deviation (38). If the “ART first” arm is found to be non-
240 inferior to the “TB results first” arm in both the mITT and PP sets, then we will assess for superiority of
241 the “ART first” approach in the mITT set. Given the expected proportion of participants with viral
242 suppression six months after enrolment in the “TB results first” arm of 75% and the non-inferiority
243 margin of 10%, a sample size of 295 participants per arm is required to have 80% power to demonstrate
244 non-inferiority.

245 The secondary endpoints of ART initiation by 7 and 28 days after enrolment, retention and engagement
246 in care, disengagement from care, lost to follow-up, SAEs, AESIs, and non-traumatic deaths will be
247 assessed for superiority in the mITT population. Secondary endpoints will be analyzed with logistic
248 regression models adjusted for country, and results will be presented as risk differences and 95%
249 confidence intervals if events allow, and otherwise be summarized descriptively. HIV viral suppression
250 at different thresholds (<40, <100, and <1000 copies/mL) will be analyzed as an explorative sensitivity
251 analysis of the primary outcome with an emphasis on effect estimates and confidence intervals. Further
252 details will be described in the statistical analysis plan.

253 **Data management and monitoring**

254 Data is collected on password-protected tablets, using a validated installation of the REDCap platform
255 (35) hosted at the University Hospital Basel, Switzerland. Data is reviewed regularly by central and local
256 data managers. Queries regarding inconsistencies and missing data are raised within the electronic data
257 capture system. REDCap includes a computer-generated time stamped audit trail. Study participants are
258 assigned a unique participant number, which is used to identify participants in the electronic case report
259 forms and in all data exports.

260 The Swiss Tropical and Public Health Institute’s Clinical Operations Unit is responsible for trial monitoring
261 in Lesotho, and the Malawi-Liverpool-Wellcome Programme Clinical Research Support Unit in Malawi.
262 The monitoring entails a systematic examination of study related activities and documents.

263 A data safety and monitoring board consisting of three independent experts will review SAE and AESI
264 reports and provide recommendations to the study team whether to pause, stop, amend, or continue
265 the trial to ensure participant safety and integrity of the trial data. No formal interim analysis will be
266 conducted.

267 **Ethical considerations**

268 The trial has been approved by the National Health Research and Ethics Committee (NH-REC) of Lesotho
269 (ID: 102-2022), the College of Medicine Research and Ethics Committee (COMREC) of Malawi (ID:
270 P.04/22/3612) and the “Ethikkommission Nordwest- und Zentralschweiz” (EKNZ) in Switzerland (ID:
271 AO_2022_00031). Substantial changes to the study protocol and relevant study documents will be
272 submitted to the involved ethics committees for approval before implementation and information will
273 be updated on the clinical trial registry.

274 The tested strategies for the timing of ART initiation relative to completion of TB investigations in PWH
275 with presumptive TB have the following risks and benefits: In the “ART first” arm, the risk of TB-IRIS is
276 increased due to the earlier initiation of ART (13) whereas the risk of pre-ART attrition from care and
277 thereby of AIDS-related complications, is reduced (7). The opposite applies to the “TB results first” arm.
278 For an in-depth risk-benefit assessment, we refer to the current WHO HIV guidelines (19) and the
279 corresponding systematic review (31). The rationale for this trial is the uncertainty about which of the
280 strategies entails a more favorable overall risk-benefit profile.

281 **Sub study: ART initiation cohort**

282 In parallel to the SaDAPT trial, we are recruiting participants aged 12 years and older, (re)initiating ART
283 at the study sites but not eligible for the SaDAPT trial into an observational ART initiation cohort. This
284 cohort shall allow to better understand the SaDAPT trial's external validity through description of
285 baseline characteristics and outcomes at the same clinics but outside a trial setting. The specific
286 objectives of the ART initiation cohort are to provide a description of baseline characteristics and
287 outcomes of PWH (re)initiating ART in primary and secondary health facilities in Malawi and Lesotho
288 and to allow for an informal comparison between PWH (re)initiating ART with and without presumptive
289 TB according to the W4SS (20). The sensitivity and specificity of the W4SS for TB case finding in PWH is
290 limited and a considerable proportion of PWH are known to have subclinical TB disease before initiating
291 ART (20,39,40). It is unclear how relevant the presence or absence of TB symptoms are for clinical
292 management and outcomes, including occurrence of active TB (41). The ART initiation cohort shall allow
293 understanding if, and if so, to what extent characteristics and outcomes among PWH with and without
294 TB symptoms who are (re)initiating ART differ. The ART initiation cohort will provide insights into the
295 current management and outcomes of PWH (re)initiating ART in Malawi and Lesotho beyond the narrow
296 question about timing of ART initiation in presumptive TB patients addressed by the SaDAPT trial.

297 Only patients requiring referral to a higher-level facility at the time of screening, patients planning to
298 move out of the facility's catchment area within the next six months or those not consenting are
299 excluded. Baseline study procedures for the ART initiation cohort are similar to the SaDAPT trial, without
300 TB investigations for participants without TB symptoms. Data is collected on the same study tablet using
301 the same REDCap instance as for the SaDAPT trial. Participants are followed-up passively, through
302 collection of data available in routine registers and lab reports via register reviews, with the possibility
303 of an in-person assessment together with the routine ART refill visit six months after enrolment.
304 Participants of the SaDAPT trial will continue to be followed-up as part of the ART initiation cohort after

305 termination of the trial after six months. Passive follow-up via register review may continue up to two
306 years after enrolment. Analysis will be by descriptive statistics. The ART initiation cohort is recruiting
307 concurrently with the SaDAPT trial and will close recruitment at the time when the final SaDAPT trial
308 participant is recruited. We estimate the prevalence of any TB symptom among PWH (re)initiating ART
309 to be between 30%-45% (23), thus between 1300 and 1800 participants are expected to be included in
310 the ART initiation cohort.

311 **Discussion**

312 SaDAPT is a pragmatic randomized non-inferiority trial conducted in Malawi and Lesotho that compares
313 the effectiveness and safety of SDI of ART (“ART first”) to ART initiation only after results of TB
314 investigations are available (“TB results first”) in PWH with presumptive TB.

315 A previous trial assessing the effectiveness of SDI in presumptive TB has provided same-day NAAT results
316 as part of the trial procedures and then started ART only in participants found to be TB negative (42).
317 However, this turnaround time for NAAT is not feasible in many settings. Another trial (SLATE II) allowed
318 SDI for people with TB symptoms only if symptoms were mild and after a negative TB LAM result (25).
319 Despite the relative simplicity of the SLATE II screening algorithm, implementation in routine practice
320 might be a considerable obstacle because a standardized severity assessment of TB symptoms requires
321 specific training of involved healthcare staff and TB LAM availability is often limited in routine practice.
322 In SaDAPT, the eligibility screening is reduced to the routine assessments required before ART initiation
323 in every non-pregnant patient, as only patients with potential CNS infection and those requiring hospital
324 admission or referral to a higher-level facility due to severe illness are excluded. Hence, we expect the
325 results of SaDAPT to be highly generalizable and relevant to practice guidelines in settings applying a
326 public health approach to ART.

327 Limitations of the pragmatic approach of the trial are related to the incomplete standardization of
328 procedures between study sites, for example the investigations to rule out or confirm TB are depending
329 on clinical judgement, local guidelines and local availability of diagnostic tools. All study sites have NAAT
330 routinely available, but turn-around times are unpredictable and other tools such as X-ray or urine-LAM
331 are available at some sites but not at others.

332 One of the main drivers determining the outcome of the trial as well as HIV outcomes in routine care is
333 attrition from care. Therefore, we minimize the trial's influence on routine practices by avoiding
334 additional study visits, with the exception of the primary endpoint assessment six months after
335 enrolment, which falls together with the routine viral load measurement. This implies that we are relying
336 on passive surveillance of adverse events. Therefore, we are only capturing events leading to patient-
337 initiated contact with the healthcare system or reporting to the study team. Hence, the SaDAPT trial
338 does not allow to reliably capture non-severe adverse events, such as mild IRIS cases.

339 SDI of ART offers considerable advantages for providers and patients compared to ART initiation only
340 after TB results are available if found to be safe and non-inferior. For providers, allowing SDI for patients
341 with presumptive TB would simplify the ART initiation processes and allow for harmonization of
342 initiation procedures independent of the presence of TB symptoms. For patients, the number of clinic
343 visits and hence loss of time and money could be considerably reduced if ART could be safely dispensed
344 on the day of first presentation.

345 Combining the data collection for the SaDAPT trial with the observational ART initiation cohort that
346 includes patients (re)initiating ART at the study facilities independent of the presence of TB symptoms
347 will enhance generalizability of the SaDAPT trial results and allow for a deeper understanding of the
348 findings in the context of the overall retention and viral suppression rates at the study facilities. Also,

349 the comparison of safety outcomes such as the incidence of TB-IRIS, active TB or SAEs will allow us to
350 check plausibility of the results found in the SaDAPT trial population.

351 **Data availability statement**

352 This protocol manuscript does not report data. We will make anonymized individual data freely available
353 on a suitable repository, such as zenodo.org, along with publication of the study results. The full protocol
354 as submitted to ethics committees is available on clinicaltrials.gov. Study results will be published in a
355 peer-reviewed journal.

356 **Trial status**

357 The first participant was recruited on October 19, 2022 and at the time of submission on June 30, 2023,
358 305 participants were enrolled in the SaDAPT trial and 431 in the ART initiation cohort.

359 **Acknowledgments**

360 We would like to thank all study staff for the dedicated work.

361 **References**

- 362 1. Ford N, Ball A, Baggaley R, Vitoria M, Low-Beer D, Penazzato M, et al. The WHO public health
363 approach to HIV treatment and care: looking back and looking ahead. *Lancet Infect Dis*. 2018
364 Mar;18(3):e76–86.
- 365 2. Joint United Nations Programme on HIV/AIDS. UNAIDS Data 2022 [Internet]. Geneva: Joint United
366 Nations Programme on HIV/AIDS; 2022 [cited 2023 Feb 14]. Available from:
367 https://www.unaids.org/en/resources/documents/2021/2021_unaids_data
- 368 3. World Health Organization. Global tuberculosis report 2022. Geneva; 2022.
- 369 4. WHO Guidelines Approved by the Guidelines Review Committee. In: *Guidelines for Managing
370 Advanced HIV Disease and Rapid Initiation of Antiretroviral Therapy*. Geneva: World Health
371 Organization Copyright © World Health Organization 2017.; 2017.
- 372 5. Rosen S, Maskew M, Fox MP, Nyoni C, Mongwenyana C, Maletse G, et al. Initiating Antiretroviral
373 Therapy for HIV at a Patient’s First Clinic Visit: The RapIT Randomized Controlled Trial. *PLoS Med*.
374 2016 May;13(5):e1002015.
- 375 6. Lilian RR, Rees K, McIntyre JA, Struthers HE, Peters RPH. Same-day antiretroviral therapy initiation
376 for HIV-infected adults in South Africa: Analysis of routine data. *PLOS ONE*. 2020;15(1):e0227572.
- 377 7. Labhardt ND, Ringera I, Lejone TI, Klimkait T, Muhairwe J, Amstutz A, et al. Effect of Offering Same-
378 Day ART vs Usual Health Facility Referral During Home-Based HIV Testing on Linkage to Care and
379 Viral Suppression Among Adults With HIV in Lesotho: The CASCADE Randomized Clinical Trial. *Jama*.
380 2018 Mar 20;319(11):1103–12.
- 381 8. Koenig SP, Dorvil N, Dévieux JG, Hedt-Gauthier BL, Riviere C, Faustin M, et al. Same-day HIV testing
382 with initiation of antiretroviral therapy versus standard care for persons living with HIV: A
383 randomized unblinded trial. Geng EH, editor. *PLOS Med*. 2017 Jul 25;14(7):e1002357.
- 384 9. Pilcher CD, Ospina-Norvell C, Dasgupta A, Jones D, Hartogensis W, Torres S, et al. The Effect of Same-
385 Day Observed Initiation of Antiretroviral Therapy on HIV Viral Load and Treatment Outcomes in a
386 US Public Health Setting. *J Acquir Immune Defic Syndr*. 2017 Jan 1;74(1):44–51.
- 387 10. Meintjes G, Lawn SD, Scano F, Maartens G, French MA, Worodria W, et al. Tuberculosis-associated
388 immune reconstitution inflammatory syndrome: case definitions for use in resource-limited
389 settings. *Lancet Infect Dis*. 2008 Aug;8(8):516–23.
- 390 11. Dhasmana DJ, Dheda K, Ravn P, Wilkinson RJ, Meintjes G. Immune reconstitution inflammatory
391 syndrome in HIV-infected patients receiving antiretroviral therapy: pathogenesis, clinical
392 manifestations and management. *Drugs*. 2008;68(2):191–208.
- 393 12. Church LWP, Chopra A, Judson MA. Paradoxical Reactions and the Immune Reconstitution
394 Inflammatory Syndrome. 2017;5(2).

- 395 13. Abay SM, Deribe K, Reda AA, Biadgilign S, Datiko D, Assefa T, et al. The Effect of Early Initiation of
396 Antiretroviral Therapy in TB/HIV-Coinfected Patients: A Systematic Review and Meta-Analysis. *J Int*
397 *Assoc Provid AIDS Care*. 2015 Dec;14(6):560–70.
- 398 14. Walker NF, Stek C, Wasserman S, Wilkinson RJ, Meintjes G. The tuberculosis-associated immune
399 reconstitution inflammatory syndrome: recent advances in clinical and pathogenesis research. *Curr*
400 *Opin HIV AIDS*. 2018 Nov;13(6):512–21.
- 401 15. Namale PE, Abdullahi LH, Fine S, Kamkuemah M, Wilkinson RJ, Meintjes G. Paradoxical TB-IRIS in
402 HIV-infected adults: a systematic review and meta-analysis. *Future Microbiol*. 2015;10(6):1077–99.
- 403 16. Török ME, Yen NT, Chau TT, Mai NT, Phu NH, Mai PP, et al. Timing of initiation of antiretroviral
404 therapy in human immunodeficiency virus (HIV)--associated tuberculous meningitis. *Clin Infect Dis*.
405 2011 Jun;52(11):1374–83.
- 406 17. Bahr N, Boulware DR, Marais S, Scriven J, Wilkinson RJ, Meintjes G. Central nervous system immune
407 reconstitution inflammatory syndrome. *Curr Infect Rep*. 2013 Dec;15(6):583–93.
- 408 18. Eshun-Wilson I, Okwen MP, Richardson M, Bicanic T. Early versus delayed antiretroviral treatment
409 in HIV-positive people with cryptococcal meningitis. *Cochrane Database Syst Rev*. 2018 Jul
410 24;7(7):Cd009012.
- 411 19. World Health Organization. Consolidated guidelines on HIV prevention, testing, treatment, service
412 delivery and monitoring: recommendations for a public health approach [Internet]. 2021 update.
413 Geneva: World Health Organization; 2021 [cited 2021 Oct 11]. Available from:
414 <https://apps.who.int/iris/handle/10665/342899>
- 415 20. Hamada Y, Lujan J, Schenkel K, Ford N, Getahun H. Sensitivity and specificity of WHO's
416 recommended four-symptom screening rule for tuberculosis in people living with HIV: a systematic
417 review and meta-analysis. *Lancet HIV*. 2018 Sep;5(9):e515–23.
- 418 21. Getahun H, Kittikraisak W, Heilig CM, Corbett EL, Ayles H, Cain KP, et al. Development of a
419 standardized screening rule for tuberculosis in people living with HIV in resource-constrained
420 settings: individual participant data meta-analysis of observational studies. *PLoS Med*. 2011 Jan
421 18;8(1):e1000391.
- 422 22. Dhana A, Hamada Y, Kengne AP, Kerkhoff AD, Rangaka MX, Kredo T, et al. Tuberculosis screening
423 among ambulatory people living with HIV: a systematic review and individual participant data meta-
424 analysis. *Lancet Infect Dis*. 2021 Nov;S147330992100387X.
- 425 23. Brennan A, Maskew M, Larson BA, Tsikhutsu I, Bii M, Vezi L, et al. Prevalence of TB symptoms,
426 diagnosis and treatment among people living with HIV (PLHIV) not on ART presenting at outpatient
427 clinics in South Africa and Kenya: baseline results from a clinical trial. *BMJ Open*. 2020 Sep
428 6;10(9):e035794.
- 429 24. Rosen S, Maskew M, Larson BA, Brennan AT, Tsikhutsu I, Fox MP, et al. Simplified clinical algorithm
430 for identifying patients eligible for same-day HIV treatment initiation (SLATE): Results from an
431 individually randomized trial in South Africa and Kenya. *PLoS Med*. 2019 Sep;16(9):e1002912.

- 432 25. Maskew M, Brennan AT, Fox MP, Vezi L, Venter WDF, Ehrenkranz P, et al. A clinical algorithm for
433 same-day HIV treatment initiation in settings with high TB symptom prevalence in South Africa: The
434 SLATE II individually randomized clinical trial. *PLoS Med.* 2020 Aug;17(8):e1003226.
- 435 26. World Health Organization. Guidelines for managing advanced HIV disease and rapid initiation of
436 antiretroviral therapy, July 2017 [Internet]. Geneva: World Health Organization; 2017 [cited 2021
437 Oct 25]. 56 p. Available from: <https://apps.who.int/iris/handle/10665/255884>
- 438 27. Lawn SD, Campbell L, Kaplan R, Little F, Morrow C, Wood R. Delays in starting antiretroviral therapy
439 in patients with HIV-associated tuberculosis accessing non-integrated clinical services in a South
440 African township. *BMC Infect Dis.* 2011 Sep 30;11:258.
- 441 28. Fox MP, Rosen S, Geldsetzer P, Bärnighausen T, Negussie E, Beanland R. Interventions to improve
442 the rate or timing of initiation of antiretroviral therapy for HIV in sub-Saharan Africa: meta-analyses
443 of effectiveness. *J Int AIDS Soc.* 2016 Jan;19(1):20888.
- 444 29. Rosen S, Fox MP, Larson BA, Sow PS, Ehrenkranz PD, Venter F, et al. Accelerating the Uptake and
445 Timing of Antiretroviral Therapy Initiation in Sub-Saharan Africa: An Operations Research Agenda.
446 *PLoS Med.* 2016 Aug;13(8):e1002106.
- 447 30. World Health Organization. Guidelines: updated recommendations on HIV prevention, infant
448 diagnosis, antiretroviral initiation and monitoring [Internet]. Geneva: World Health Organization;
449 2021 [cited 2021 Nov 17]. Available from: <https://apps.who.int/iris/handle/10665/340190>
- 450 31. Burke RM, Rickman HM, Singh V, Kalua T, Labhardt ND, Hosseinipour M, et al. Same-day
451 antiretroviral therapy initiation for people living with HIV who have tuberculosis symptoms: a
452 systematic review. *HIV Med.* 2021 Sep 15;hiv.13169.
- 453 32. Eaton JW, Dwyer-Lindgren L, Gutreuter S, O'Driscoll M, Stevens O, Bajaj S, et al. Naomi: a new
454 modelling tool for estimating HIV epidemic indicators at the district level in sub-Saharan Africa. *J Int
455 AIDS Soc* [Internet]. 2021 Sep [cited 2022 Mar 5];24(S5). Available from:
456 <https://onlinelibrary.wiley.com/doi/10.1002/jia2.25788>
- 457 33. Feasey HRA, Khundi M, Nzawa Soko R, Nightingale E, Burke RM, Henrion MYR, et al. Prevalence of
458 Bacteriologically-Confirmed Tuberculosis in Urban Blantyre, Malawi 2019-20: Substantial Decline
459 Compared to 2013-14 National Survey [Internet]. *Epidemiology*; 2023 [cited 2023 May 25]. Available
460 from: <http://medrxiv.org/lookup/doi/10.1101/2023.04.20.23288872>
- 461 34. WHO Guidelines Approved by the Guidelines Review Committee. In: Consolidated Guidelines on the
462 Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public
463 Health Approach. Geneva: World Health Organization Copyright © World Health Organization
464 2016.; 2016.
- 465 35. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, et al. The REDCap consortium:
466 Building an international community of software platform partners. *J Biomed Inform.* 2019/05/09
467 ed. 2019 Jul;95:103208–103208.

- 468 36. Kahan BC, Morris TP. Reporting and analysis of trials using stratified randomisation in leading
469 medical journals: review and reanalysis. *BMJ*. 2012 Sep 14;345(sep14 1):e5840–e5840.
- 470 37. Pocock SJ, Assmann SE, Enos LE, Kasten LE. Subgroup analysis, covariate adjustment and baseline
471 comparisons in clinical trial reporting: current practice and problems. *Stat Med*. 2002 Oct
472 15;21(19):2917–30.
- 473 38. Committee for Proprietary Medicinal Products (CPMP). Points to consider on switching between
474 superiority and non-inferiority. *Br J Clin Pharmacol*. 2001 Sep;52(3):223–8.
- 475 39. Bajema KL, Bassett IV, Coleman SM, Ross D, Freedberg KA, Wald A, et al. Subclinical tuberculosis
476 among adults with HIV: clinical features and outcomes in a South African cohort. *BMC Infect Dis*.
477 2019 Dec;19(1):14.
- 478 40. Modi S, Cavanaugh JS, Shiraishi RW, Alexander HL, McCarthy KD, Burmen B, et al. Performance of
479 Clinical Screening Algorithms for Tuberculosis Intensified Case Finding among People Living with HIV
480 in Western Kenya. Fernandez-Reyes D, editor. *PLOS ONE*. 2016 Dec 9;11(12):e0167685.
- 481 41. Drain PK, Bajema KL, Dowdy D, Dheda K, Naidoo K, Schumacher SG, et al. Incipient and Subclinical
482 Tuberculosis: a Clinical Review of Early Stages and Progression of Infection. *Clin Microbiol Rev*
483 [Internet]. 2018 Oct [cited 2022 Feb 1];31(4). Available from:
484 <https://journals.asm.org/doi/10.1128/CMR.00021-18>
- 485 42. Dorvil N, Rivera VR, Riviere C, Berman R, Severe P, Bang H, et al. Same-day testing with initiation of
486 antiretroviral therapy or tuberculosis treatment versus standard care for persons presenting with
487 tuberculosis symptoms at HIV diagnosis: A randomized open-label trial from Haiti. *PLOS Med*. 2023
488 Jun 9;20(6):e1004246.


489

490

491 **S1 Spirit Checklist.**

TIMEPOINT	0 Screening enrolment	TB results review	28 days Register review	Week 26 (22-30) Study visit	30 week Register review	Weeks 31-40 Tracing
Eligibility screening	X					
Informed consent	X					
Randomization and arm allocation	X					
INTERVENTION:						
ART initiation ("ART first arm")	X					
ART initiation ("TB results first arm")		X				
ASSESSMENTS:						
Sociodemographic characteristics ascertained	X					
Brief clinical assessment	X			X		
CD4 cell count	X					
CrAg test if CD4 <200 cells/ml or clinical indication	X					
Start TB tests	X					
Surveillance of SAEs, AESIs, active TB disease	X	X		X		
HIV Viral Load				X		(X)
ART adherence and refills since enrolment				X		
Review of routine registers to check for missing data			X		X	

Figure



Figure